Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $935.23M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.21M
Average 0.31M
SLN EBITDA Margin
EBITDA as a percentage of revenue.
Silence Therapeutics plcNASDAQ: SLN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -3519.2%
EBITDA Margin was -3519.2% in Q1 FY2026, up 16475.3 pp from a year earlier. On a trailing-twelve-month basis it was -8478.5%. Over 3 fiscal years it narrowed by 15524.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -100.0% for the fiscal year ending Dec 2026, up from -15750.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -3519.2%+30766.1 pp QoQ
- Last fiscal yearDec 2025
- -15750.6%-15637.4 pp YoY
- LTMMar 2026
- -8478.5%— YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -15750.6%
- Year-over-year change
- —
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -15750.6% | — |
| FY2024 | 2024-12-31 | -113.2% | +82.9pp |
| FY2023 | 2023-12-31 | -196.2% | +30.1pp |
| FY2022 | 2022-12-31 | -226.2% | +139.6pp |
| FY2021 | 2021-12-31 | -365.9% | — |
EBITDA Margin vs competitors
How SLN compares with its peers on the latest reported figures
- SLN's LTM Mar 2026 EBITDA Margin of -8478.5% is the lowest of the 8 companies compared; the peer median is -148.9%.
- Over three fiscal years its change of -15524.4 pp compares with a peer median of +21.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 5.7% | +10.5 pp | +34.3 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Sep 2026 | -133.9% | -153.8 pp | -60.9 pp | |
| LTM Mar 2026 | -148.9% | -100.7 pp | -100.7 pp | |
| LTM Mar 2026 | -243.2% | -144.4 pp | +3681.3 pp | |
| LTM Mar 2026 | -319.0% | -184.3 pp | +1328.5 pp | |
| FY2025 | -410.9% | — | — | |
| LTM Mar 2026 | -8478.5% | — | -15524.4 pp | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding SLN) | -148.9% | -122.5 pp | +21.5 pp | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 12.42M | 17.65M | 25.38M | 43.26M | 559K |
| Cost of Revenue | 7.46M | 10.97M | 10.32M | 11.81M | 215K |
| Gross Profit | 4.96M | 6.68M | 15.06M | 31.45M | 344K |
| Gross Margin | 39.9% | 37.8% | 59.3% | 72.7% | 61.5% |
| Research & Development | 30.77M | 35.5M | 44.03M | 67.88M | 67.75M |
| Selling, General & Admin | 20.01M | 20.94M | 20.64M | 26.88M | 22.34M |
| Operating Expenses | 50.77M | 56.44M | 64.66M | 94.77M | 90.1M |
| Depreciation & Amortization | 427K | 485.86K | 498K | 593K | 555K |
| EBITDA | (45.42M) | (39.94M) | (49.78M) | (48.99M) | (88.05M) |
| EBITDA Margin | -365.9% | -226.2% | -196.2% | -113.2% | -15750.6% |
| Operating Income | (45.81M) | (49.76M) | (49.6M) | (63.32M) | (89.75M) |
| Operating Margin | -369.0% | -281.9% | -195.5% | -146.4% | -16056.0% |
| Interest Income | 10K | 226K | 1.45M | 4.47M | 3.48M |
| Interest Expense | 8K | 47K | 34K | 0 | 0 |
| Other Income / Expenses | (42K) | 9.29M | (706K) | 18.86M | 1.15M |
| Income Before Tax | (45.86M) | (40.47M) | (50.31M) | (44.46M) | (88.6M) |
| Pre-Tax Margin | -369.4% | -229.3% | -198.3% | -102.8% | -15849.9% |
| Income Tax Expense | (6.45M) | 560.85K | (7.04M) | 845K | 11K |
| Net Income | (39.41M) | (41.03M) | (43.27M) | (45.31M) | (88.61M) |
| Net Margin | -317.4% | -232.4% | -170.5% | -104.7% | -15851.9% |
| EPS (Basic) | (1.35) | (3.78) | (3.48) | (2.37) | (1.89) |
| EPS (Diluted) | (1.35) | (3.78) | (3.48) | (2.37) | (1.89) |
| Weighted Avg Shares | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
| Weighted Avg Shares (Diluted) | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.